UPMC ven­ture arm ear­marks $1B in­vest­ment in life sci­ences

UPMC En­ter­pris­es, which most re­cent­ly backed Were­wolf Ther­a­peu­tics, is now set­ting aside $1 bil­lion to de­vel­op new drugs, de­vices and di­ag­nos­tics.

Ini­tial­ly fo­cused on im­munother­a­pies for can­cer, trans­plan­ta­tion and ag­ing, the Uni­ver­si­ty of Pitts­burgh Med­ical Cen­ter’s (UPMC) ven­ture cap­i­tal arm has ex­pand­ed its fo­cus to in­clude reti­nal and res­pi­ra­to­ry dis­ease, au­toim­mune dis­eases and neu­roin­flam­ma­tion among oth­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER